361 related articles for article (PubMed ID: 16821145)
1. Posttranslational phosphorylation of mutant p53 protein in tumor development.
Matsumoto M; Furihata M; Ohtsuki Y
Med Mol Morphol; 2006 Jun; 39(2):79-87. PubMed ID: 16821145
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
3. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.
Rinaldo C; Prodosmo A; Mancini F; Iacovelli S; Sacchi A; Moretti F; Soddu S
Mol Cell; 2007 Mar; 25(5):739-50. PubMed ID: 17349959
[TBL] [Abstract][Full Text] [Related]
4. Promyelocytic leukemia protein is required for gain of function by mutant p53.
Haupt S; di Agostino S; Mizrahi I; Alsheich-Bartok O; Voorhoeve M; Damalas A; Blandino G; Haupt Y
Cancer Res; 2009 Jun; 69(11):4818-26. PubMed ID: 19487292
[TBL] [Abstract][Full Text] [Related]
5. Signaling to p53: breaking the posttranslational modification code.
Appella E; Anderson CW
Pathol Biol (Paris); 2000 Apr; 48(3):227-45. PubMed ID: 10858956
[TBL] [Abstract][Full Text] [Related]
6. Post-translational modifications of p53 tumor suppressor: determinants of its functional targets.
Taira N; Yoshida K
Histol Histopathol; 2012 Apr; 27(4):437-43. PubMed ID: 22374721
[TBL] [Abstract][Full Text] [Related]
7. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers.
Craig AL; Burch L; Vojtesek B; Mikutowska J; Thompson A; Hupp TR
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):133-41. PubMed ID: 10432310
[TBL] [Abstract][Full Text] [Related]
8. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
9. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
[TBL] [Abstract][Full Text] [Related]
11. Mutation of phosphoserine 389 affects p53 function in vivo.
Hao M; Lowy AM; Kapoor M; Deffie A; Liu G; Lozano G
J Biol Chem; 1996 Nov; 271(46):29380-5. PubMed ID: 8910602
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
Shono T; Tofilon PJ; Schaefer TS; Parikh D; Liu TJ; Lang FF
Cancer Res; 2002 Feb; 62(4):1069-76. PubMed ID: 11861384
[TBL] [Abstract][Full Text] [Related]
13. p53 mutations in cancer.
Muller PA; Vousden KH
Nat Cell Biol; 2013 Jan; 15(1):2-8. PubMed ID: 23263379
[TBL] [Abstract][Full Text] [Related]
14. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.
Martinez-Rivera M; Siddik ZH
Biochem Pharmacol; 2012 Apr; 83(8):1049-62. PubMed ID: 22227014
[TBL] [Abstract][Full Text] [Related]
15. The absence of Ser389 phosphorylation in p53 affects the basal gene expression level of many p53-dependent genes and alters the biphasic response to UV exposure in mouse embryonic fibroblasts.
Bruins W; Bruning O; Jonker MJ; Zwart E; van der Hoeven TV; Pennings JL; Rauwerda H; de Vries A; Breit TM
Mol Cell Biol; 2008 Mar; 28(6):1974-87. PubMed ID: 18195040
[TBL] [Abstract][Full Text] [Related]
16. Ser392 phosphorylation regulates the oncogenic function of mutant p53.
Yap DB; Hsieh JK; Zhong S; Heath V; Gusterson B; Crook T; Lu X
Cancer Res; 2004 Jul; 64(14):4749-54. PubMed ID: 15256442
[TBL] [Abstract][Full Text] [Related]
17. [Dominant negative activity of mutated p53 proteins].
Dridi W; Krabchi K; Gadji M; Lavoie J; Bronsard M; Fetni R; Drouin R
Med Sci (Paris); 2006 Mar; 22(3):301-7. PubMed ID: 16527213
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.
Sugikawa E; Hosoi T; Yazaki N; Gamanuma M; Nakanishi N; Ohashi M
Anticancer Res; 1999; 19(4B):3099-108. PubMed ID: 10652599
[TBL] [Abstract][Full Text] [Related]
19. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
20. Enhanced phosphorylation of p53 serine 18 following DNA damage in DNA-dependent protein kinase catalytic subunit-deficient cells.
Araki R; Fukumura R; Fujimori A; Taya Y; Shiloh Y; Kurimasa A; Burma S; Li GC; Chen DJ; Sato K; Hoki Y; Tatsumi K; Abe M
Cancer Res; 1999 Aug; 59(15):3543-6. PubMed ID: 10446957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
